Working to Eradicate Gynecologic Cancers

RF4
Focused Plenary IV: Innovations in Immunotherapy

Sunday, March 23, 2014: 1:45 PM-3:00 PM
Ballroom D (Tampa Convention Center)
Description:
Moderator:  Terri L. Cornelison, MD, PhD, National Institues of Health, Bethesda, MD
1:45 PM
Moderator Introductions in Focused Plenary: Focused Plenary IV: Innovations in Immunotherapy
T. L. Cornelison
National Institues of Health, Bethesda, MD
 

 
1:51 PM
70 - Focused Plenary
Phase I evaluation of therapeutic HPV16 E7 vaccination before resection of HPV16+ CIN2/3
W. K. Huh1, R. D. Alvarez1, L. Maldonado2, C. Wang2, T. C. Wu2 and C. Trimble2
1University of Alabama at Birmingham, Birmingham, AL, 2Johns Hopkins Medical Institutions, Baltimore, MD
 

 
2:00 PM
71 - Focused Plenary
Phase II trial of paclitaxel, 13-cis retinoic acid, and interferon-alfa-2b in the treatment of advanced stage or recurrent cervical cancer
M. Song1, R. Di Paola1, B. M. Cracchiolo2, D. G. Gibbon1, M. Hellmann1, W. Nieves1, A. P. Vaidya3, A. Wagreich1, W. Shih1 and L. Rodriguez-Rodriguez1
1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 2Rutgers New Jersey Medical School, Newark, NJ, 3John Theuerer Cancer Center, Hackensack, NJ
 

 
2:09 PM
72 - Focused Plenary
Nationwide assessment of human papillomavirus (HPV) genotypes in cancers: implications for prevention and monitoring impact of current and future (9-valent) HPV vaccines in the United States
M. T. Goodman1, E. Unger2, T. Thompson2, C. F. Lynch3, M. Steinau2, B. Hernandez4, C. Hopenhayn5, E. J. Wilkinson6, G. C. Copeland7 and M. Saraiya2
1Cedars-Sinai Medical Center, Los Angeles, CA, 2Centers for Disease Control and Prevention, Atlanta, GA, 3University of Iowa, Iowa City, IA, 4University of Hawaii Cancer Center, Honolulu, HI, 5University of Kentucky, Lexington, KY, 6University of Florida College of Medicine, Gainesville, FL, 7Michigan Department of Community Health, Lansing, MI
 

 
2:20 PM
Lecturette
W. K. Huh
University of Alabama at Birmingham, Birmingham, AL
 

 
2:26 PM
73 - Focused Plenary
Combination immunotherapy enhances survival in patients with recurrent ovarian cancer
J. L. Tanyi, E. Zsiros, C. L. Chiang, D. Torigian, M. A. Morgan, W. T. Hwang, H. L. Nisenbaum, L. Kandalaft and G. Coukos
University of Pennsylvania, Philadelphia, PA
 

 
2:35 PM
74 - Focused Plenary
A phase I trial of a DNA plasmid-based vaccine targeting insulin-like growth factor binding protein-2 (IGFBP-2) in patients with advanced ovarian cancer: preliminary safety and immunogenicity
J. B. Liao, D. L. Cecil, J. Reichow, S. Parker, D. Higgins, J. Childs, E. Broussard, A. Coveler, L. Salazar and M. L. Disis
University of Washington, Seattle, WA
 

 
2:44 PM
Lecturette
M. B. Jones
Cancer Centers of North Carolina, Raleigh, NC
 
2:49 PM
Questions & Floor Discussion
 
See more of: Focused Plenary
<< Previous Course | Next Course >>